← Back to Search

Glaucoma Suspects for Glaucoma

N/A
Recruiting
Research Sponsored by Jorvec Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediately after measurement
Awards & highlights

Study Summary

Glaucoma is a progressive disease resulting in blindness. Determining the onset of the disease is critical so patients may obtain treatment to preserve useful vision. This study will collect data from a population of glaucoma suspects (with positive factors for the disease but with normal vision) along with a population of age matched controls using the pattern electroretinogram (PERG) and other standard eye tests for glaucoma. The PERG measures the function of retinal ganglion cells (RGCs) which come together to form the optic nerve. RGCs may become dysfunctional before dying. The Continuous loop deconvolution technique (CLAD) will be used to extract transient PERG responses in both glaucoma suspects and age matched controls. All patients will be monitored with PERG, Optic Coherence Tomography (OCT) and other ancillary tests over 2 years. CLAD will be compared with conventional techniques of monitoring glaucoma (standard PERG, OCT, visual field etc) to see if the CLAD is better at distinguishing between glaucoma suspects and controls.

Eligible Conditions
  • Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediately after measurement
This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately after measurement for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PERG Amplitude
PERG Latency

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Glaucoma SuspectsExperimental Treatment1 Intervention
Patients with suspicion of glaucoma based on positive factors of disease.
Group II: ControlsActive Control1 Intervention
Age matched controls to the glaucoma suspect group with no indications of glaucoma.

Find a Location

Who is running the clinical trial?

Jorvec Corp.Lead Sponsor
University of MiamiOTHER
910 Previous Clinical Trials
411,531 Total Patients Enrolled
10 Trials studying Glaucoma
2,402 Patients Enrolled for Glaucoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~60 spots leftby Jun 2025